| Q37760846 | "Without Ub I am nothing": NEMO as a multifunctional player in ubiquitin-mediated control of NF-kappaB activation |
| Q36076152 | A Structural View of Negative Regulation of the Toll-like Receptor-Mediated Inflammatory Pathway. |
| Q55456772 | A case of multiple familial trichoepitheliomas responding to treatment with the Hedgehog signaling pathway inhibitor vismodegib. |
| Q35212880 | A genome-wide association study in catfish reveals the presence of functional hubs of related genes within QTLs for columnaris disease resistance |
| Q37576755 | A pro-inflammatory role of deubiquitinating enzyme cylindromatosis (CYLD) in vascular smooth muscle cells. |
| Q34887377 | A rare case of multiple segmental eccrine spiradenomas. |
| Q34828781 | A reporter screen in a human haploid cell line identifies CYLD as a constitutive inhibitor of NF-κB. |
| Q64052727 | ALPK1 hotspot mutation as a driver of human spiradenoma and spiradenocarcinoma |
| Q47125969 | ANGPTL8 negatively regulates NF-κB activation by facilitating selective autophagic degradation of IKKγ. |
| Q33764288 | Action of YM155 on clear cell renal cell carcinoma does not depend on survivin expression levels |
| Q33808690 | An atlas of altered expression of deubiquitinating enzymes in human cancer |
| Q36712027 | Autophagy in acute kidney injury |
| Q90409382 | Bisdemethoxycurcumin Inhibits Hepatocellular Carcinoma Proliferation Through Akt Inactivation via CYLD-Mediated Deubiquitination |
| Q47137012 | CYLD Deubiquitinase Negatively Regulates High Glucose-Induced NF-κB Inflammatory Signaling in Mesangial Cells. |
| Q35475874 | CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. |
| Q37698907 | CYLD coordinates with EB1 to regulate microtubule dynamics and cell migration |
| Q34647548 | CYLD deletion triggers nuclear factor-κB-signaling and increases cell death resistance in murine hepatocytes. |
| Q92577603 | CYLD dysregulation in pathogenesis of sporadic inclusion body myositis |
| Q34795465 | CYLD enhances severe listeriosis by impairing IL-6/STAT3-dependent fibrin production |
| Q34452444 | CYLD mediates ciliogenesis in multiple organs by deubiquitinating Cep70 and inactivating HDAC6. |
| Q35412516 | CYLD negatively regulates nontypeable Haemophilus influenzae-induced IL-8 expression via phosphatase MKP-1-dependent inhibition of ERK. |
| Q35916665 | CYLD negatively regulates transforming growth factor-β-signalling via deubiquitinating Akt |
| Q34584522 | CYLD regulates RhoA activity by modulating LARG ubiquitination |
| Q24301471 | CYLD regulates angiogenesis by mediating vascular endothelial cell migration |
| Q57033611 | CYLD suppression enhances the pro-inflammatory effects and hyperproliferation of rheumatoid arthritis fibroblast-like synoviocytes by enhancing NF-κB activation |
| Q39210955 | CYLD, A20 and OTULIN deubiquitinases in NF-κB signaling and cell death: so similar, yet so different |
| Q35565726 | CYLD-mediated signaling and diseases. |
| Q37846231 | CYLD: a deubiquitination enzyme with multiple roles in cancer. |
| Q38875965 | Concise Review: Fate Determination of Stem Cells by Deubiquitinating Enzymes |
| Q37391414 | Cycles of ubiquitination and deubiquitination critically regulate growth factor-mediated activation of Akt signaling |
| Q87840838 | Cylindromatosis gene CYLD regulates hepatocyte growth factor expression in hepatic stellate cells through interaction with histone deacetylase 7 |
| Q47850926 | Cylindromatosis mediates neuronal cell death in vitro and in vivo. |
| Q88337377 | DNA damage-induced nuclear factor-kappa B activation and its roles in cancer progression |
| Q39426164 | De-ubiquitinating protease USP2a targets RIP1 and TRAF2 to mediate cell death by TNF. |
| Q50420978 | Deubiquitinases A20 and CYLD modulate costimulatory signaling via CD137 (4-1BB). |
| Q90583387 | Deubiquitinases as pivotal regulators of T cell functions |
| Q46734603 | Deubiquitinating enzyme CYLD mediates pressure overload-induced cardiac maladaptive remodeling and dysfunction via downregulating Nrf2. |
| Q84504928 | Differential requirement of IKK2 for CYLD-dependent representation of thymic and peripheral T-cell populations |
| Q38608670 | Dishevelled proteins and CYLD reciprocally regulate each other in CML cell lines |
| Q36524131 | Downregulation of miR-362-5p inhibits proliferation, migration and invasion of human breast cancer MCF7 cells |
| Q27930260 | Dynamic ubiquitination of the mitogen-activated protein kinase kinase (MAPKK) Ste7 determines mitogen-activated protein kinase (MAPK) specificity. |
| Q54334679 | Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. |
| Q46530615 | Electroacupuncture Suppresses the NF-κB Signaling Pathway by Upregulating Cylindromatosis to Alleviate Inflammatory Injury in Cerebral Ischemia/Reperfusion Rats |
| Q24622802 | Emerging role of Lys-63 ubiquitination in protein kinase and phosphatase activation and cancer development |
| Q37674364 | Emerging roles of deubiquitinases in cancer-associated pathways |
| Q37410632 | Emerging therapies targeting the ubiquitin proteasome system in cancer |
| Q34549536 | Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations |
| Q49789112 | Frequent and differential mutations of the CYLD gene in basal cell salivary neoplasms: linkage to tumor development and progression |
| Q37900457 | From MALT lymphoma to the CBM signalosome: three decades of discovery |
| Q87966506 | Fucose-specific DC-SIGN signalling directs T helper cell type-2 responses via IKKε- and CYLD-dependent Bcl3 activation |
| Q52970760 | Functional nature of a novel mutant CYLD observed in pediatric lymphoblastic B-cell leukemia. |
| Q38149113 | Genetic and microbial factors modulating the ubiquitin proteasome system in inflammatory bowel disease |
| Q104439980 | Global BioID-based SARS-CoV-2 proteins proximal interactome unveils novel ties between viral polypeptides and host factors involved in multiple COVID19-associated mechanisms |
| Q26772317 | Hepatocellular carcinoma mouse models: Hepatitis B virus-associated hepatocarcinogenesis and haploinsufficient tumor suppressor genes |
| Q37225362 | High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid |
| Q35090534 | Human T-cell lymphotropic virus: a model of NF-κB-associated tumorigenesis |
| Q90622386 | Human papillomavirus and the landscape of secondary genetic alterations in oral cancers |
| Q34227712 | Hypoxia suppresses cylindromatosis (CYLD) expression to promote inflammation in glioblastoma: possible link to acquired resistance to anti-VEGF therapy. |
| Q39166988 | Immune defects caused by mutations in the ubiquitin system |
| Q38212818 | Immune diseases caused by mutations in kinases and components of the ubiquitin system |
| Q53203833 | Inactivation of CYLD in intestinal epithelial cells exacerbates colitis-associated colorectal carcinogenesis - a short report. |
| Q36815462 | Inhibition of PDE4B suppresses inflammation by increasing expression of the deubiquitinase CYLD. |
| Q82533106 | It takes two to tango: a new couple in the family of ubiquitin-editing complexes |
| Q35971438 | K63-linked ubiquitination in kinase activation and cancer |
| Q39177871 | Linear polyubiquitin chains: a new modifier involved in NFκB activation and chronic inflammation, including dermatitis. |
| Q54171066 | Linear ubiquitin chains: NF-κB signalling, cell death and beyond. |
| Q28082899 | Linear ubiquitination in immunity |
| Q27027872 | Linear ubiquitination signals in adaptive immune responses |
| Q41625334 | MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage |
| Q38495157 | MALT1--a universal soldier: multiple strategies to ensure NF-κB activation and target gene expression |
| Q37688166 | MYCN promotes neuroblastoma malignancy by establishing a regulatory circuit with transcription factor AP4. |
| Q57072708 | Mechanisms of Regulated and Dysregulated CARD11 Signaling in Adaptive Immunity and Disease |
| Q38687124 | Mechanisms of regulation and diversification of deubiquitylating enzyme function. |
| Q42145532 | MiR-501-5p regulates CYLD expression and promotes cell proliferation in human hepatocellular carcinoma |
| Q28260580 | MicroRNA and transcription factor co-regulatory network analysis reveals miR-19 inhibits CYLD in T-cell acute lymphoblastic leukemia |
| Q35535497 | MicroRNA transcriptomes of distinct human NK cell populations identify miR-362-5p as an essential regulator of NK cell function |
| Q57052672 | MicroRNA-301b promotes cell proliferation and apoptosis resistance in triple-negative breast cancer by targeting CYLD |
| Q37562273 | MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-κB signaling |
| Q35273755 | MicroRNA-500 sustains nuclear factor-κB activation and induces gastric cancer cell proliferation and resistance to apoptosis |
| Q24316185 | Mitochondrially localised MUL1 is a novel modulator of antiviral signaling |
| Q38723429 | Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. |
| Q34648225 | Mutations of epigenetic regulatory genes are common in thymic carcinomas |
| Q35232248 | NF-κB and cancer: a paradigm of Yin-Yang. |
| Q37374081 | NF-κB as a Target for Oncogenic Viruses |
| Q27021276 | NF-κB in inflammation and renal diseases |
| Q38392308 | NF-κB induction of the SUMO protease SENP2: A negative feedback loop to attenuate cell survival response to genotoxic stress. |
| Q38000159 | NFκB and ubiquitination: partners in disarming RIPK1-mediated cell death |
| Q37884644 | Negative regulation of NF-κB and its involvement in rheumatoid arthritis |
| Q24294696 | OTULIN antagonizes LUBAC signaling by specifically hydrolyzing Met1-linked polyubiquitin |
| Q90776305 | OTULIN protects the liver against cell death, inflammation, fibrosis, and cancer |
| Q33849388 | Oncogenic activation of NF-kappaB. |
| Q40977712 | Oncogenic miR-210-3p promotes prostate cancer cell EMT and bone metastasis via NF-κB signaling pathway. |
| Q33847645 | Optineurin is required for CYLD-dependent inhibition of TNFα-induced NF-κB activation |
| Q35617725 | Optineurin regulates the interferon response in a cell cycle-dependent manner |
| Q37863593 | PTMs in conversation: activity and function of deubiquitinating enzymes regulated via post-translational modifications |
| Q40044695 | Prion protein is required for tumor necrosis factor alpha (TNFα)-triggered nuclear factor kappa B (NF-κB) signaling and cytokine production. |
| Q36498982 | Proinflammatory mediators alter expression of nuclear factor kappa B-regulating deubiquitinases in sinonasal epithelial cells |
| Q57821113 | Proteasome biology and therapeutics in cardiac diseases |
| Q41487133 | Protective dendritic cell responses against listeriosis induced by the short form of the deubiquitinating enzyme CYLD are inhibited by full-length CYLD. |
| Q34722684 | Protein ubiquitination in lymphoid malignancies |
| Q36474924 | Receptor-Interacting Protein Kinase-2 Inhibition by CYLD Impairs Antibacterial Immune Responses in Macrophages |
| Q34799443 | Regulation of Akt signaling activation by ubiquitination |
| Q26778774 | Regulation of Met1-linked polyubiquitin signalling by the deubiquitinase OTULIN |
| Q37985541 | Regulation of NF-κB signaling by the A20 deubiquitinase |
| Q35534397 | Regulation of antiviral innate immunity by deubiquitinase CYLD. |
| Q33878486 | Regulation of natural killer T-cell development by deubiquitinase CYLD |
| Q26860148 | Regulation of nuclear factor-κB in autoimmunity |
| Q37902868 | Return to homeostasis: downregulation of NF-κB responses |
| Q89555530 | Reversal of CYLD phosphorylation as a novel therapeutic approach for adult T-cell leukemia/lymphoma (ATLL) |
| Q37596666 | Role of microRNAs in inflammation-associated liver cancer |
| Q38289055 | Role of the ubiquitin proteasome system in hematologic malignancies. |
| Q38530641 | Roles of linear ubiquitinylation, a crucial regulator of NF-κB and cell death, in the immune system |
| Q26798264 | Roles of miR-182 in sensory organ development and cancer |
| Q41728570 | SPATA2: New insights into the assembly of the TNFR signaling complex |
| Q42730614 | Salvianolic Acid A Inhibits OX-LDL Effects on Exacerbating Choroidal Neovascularization via Downregulating CYLD. |
| Q33693806 | Signaling to NF-kappaB: regulation by ubiquitination |
| Q64056729 | Sishen Wan Ameliorated Trinitrobenzene-Sulfonic-Acid-Induced Chronic Colitis NEMO/NLK Signaling Pathway |
| Q34293056 | Specificity and promiscuity in human glutaminase interacting protein recognition: insight from the binding of the internal and C-terminal motif |
| Q37194681 | Structural basis of signal transduction in the TNF receptor superfamily |
| Q37728927 | Synergistic and feedback signaling mechanisms in the regulation of inflammation in respiratory infections |
| Q34174201 | T-cell receptor-induced JNK activation requires proteolytic inactivation of CYLD by MALT1. |
| Q28085394 | TCR signaling to NF-κB and mTORC1: Expanding roles of the CARMA1 complex |
| Q36659217 | TGF-β induces miR-182 to sustain NF-κB activation in glioma subsets. |
| Q39056566 | TRAF6-mediated ubiquitination of NEMO requires p62/sequestosome-1. |
| Q24300508 | TWEAK induces apoptosis through a death-signaling complex comprising receptor-interacting protein 1 (RIP1), Fas-associated death domain (FADD), and caspase-8 |
| Q54458596 | The Akt DUBbed InAktive. |
| Q45018645 | The IKKε kinase in breast cancer: from oncogenesis to treatment resistance |
| Q37620626 | The LEF1/CYLD axis and cIAPs regulate RIP1 deubiquitination and trigger apoptosis in selenite-treated colorectal cancer cells. |
| Q64924690 | The Many Roles of Ubiquitin in NF-κB Signaling. |
| Q38694587 | The co-regulatory networks of tumor suppressor genes, oncogenes, and miRNAs in colorectal cancer |
| Q59460656 | The cylindromatosis (CYLD) gene and head and neck tumorigenesis |
| Q35562497 | The deubiquitinase CYLD targets Smad7 protein to regulate transforming growth factor β (TGF-β) signaling and the development of regulatory T cells |
| Q24302203 | The deubiquitinating enzyme CYLD controls apical docking of basal bodies in ciliated epithelial cells |
| Q34695640 | The dynamics and mechanism of SUMO chain deconjugation by SUMO-specific proteases |
| Q52323058 | The fructose-2,6-bisphosphatase TIGAR suppresses NF-κB signaling by directly inhibiting the linear ubiquitin assembly complex LUBAC. |
| Q39147238 | The histone deacetylase inhibitor vorinostat prevents TNFα-induced necroptosis by regulating multiple signaling pathways |
| Q28975763 | The paracaspase MALT1 mediates CARD14-induced signaling in keratinocytes |
| Q37714303 | The regulatory crosstalk between kinases and proteases in cancer |
| Q37781736 | The role of deubiquitinating enzymes in apoptosis |
| Q64288182 | The role of ubiquitin-specific peptidases in cancer progression |
| Q82244596 | The ubiquitin proteasome system and its involvement in cell death pathways |
| Q38026746 | Toward an integrative view of Optineurin functions |
| Q55031782 | Triad3a induces the degradation of early necrosome to limit RipK1-dependent cytokine production and necroptosis. |
| Q33809154 | Truncation of the deubiquitinating domain of CYLD in myelomonocytic cells attenuates inflammatory responses |
| Q64236590 | Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer |
| Q37701767 | Tumor necrosis factor-mediated cell death: to break or to burst, that's the question |
| Q40607338 | Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner |
| Q34503492 | Ubiquitin becomes ubiquitous in cancer: emerging roles of ubiquitin ligases and deubiquitinases in tumorigenesis and as therapeutic targets |
| Q37875076 | Ubiquitin-specific proteases as cancer drug targets |
| Q55371625 | Ubiquitination and deubiquitination emerge as players in idiopathic pulmonary fibrosis pathogenesis and treatment. |
| Q37849576 | Ubiquitination of E3 ligases: self-regulation of the ubiquitin system via proteolytic and non-proteolytic mechanisms |
| Q37893455 | Ubiquitylation in apoptosis: a post-translational modification at the edge of life and death |
| Q38021448 | Ubiquitylation in immune disorders and cancer: from molecular mechanisms to therapeutic implications |
| Q93341036 | Vitamin E δ-tocotrienol inhibits TNF-α-stimulated NF-κB activation by up-regulation of anti-inflammatory A20 via modulation of sphingolipid including elevation of intracellular dihydroceramides |
| Q37323204 | Whole-exome sequencing identifies multiple loss-of-function mutations of NF-κB pathway regulators in nasopharyngeal carcinoma. |
| Q38165824 | Yin and yang of tumor inflammation: how innate immune suppressors shape the tumor microenvironments |
| Q53285080 | [CYLD deubiquitinase as a recurrent target in oncogenic processes]. |
| Q37565531 | miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression |
| Q47821872 | miR-181d regulates human dendritic cell maturation through NF-κB pathway. |
| Q36596742 | miR-486 sustains NF-κB activity by disrupting multiple NF-κB-negative feedback loops. |
| Q39275998 | p47 negatively regulates IKK activation by inducing the lysosomal degradation of polyubiquitinated NEMO. |